pLX302 ID2-V5 puro
(Plasmid
#83096)
-
PurposeLentiviral vector for constitutive expression of human ID2 with C-terminal V5 tag
-
Depositing Lab
-
Sequence Information
Full plasmid sequence is not available for this item.
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 83096 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepLX302
-
Backbone manufacturerAddgene #25896
- Backbone size w/o insert (bp) 9573
-
Vector typeMammalian Expression, Lentiviral
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberLow Copy
Gene/Insert
-
Gene/Insert nameID2
-
Alt nameinhibitor of DNA binding 2, HLH protein
-
SpeciesH. sapiens (human)
-
Insert Size (bp)405
-
GenBank IDNM_002166
-
Entrez GeneID2 (a.k.a. GIG8, ID2A, ID2H, bHLHb26)
-
Tag
/ Fusion Protein
- V5 (C terminal on backbone)
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer CMV-F
- 3′ sequencing primer WPRE-R (Common Sequencing Primers)
Resource Information
-
A portion of this plasmid was derived from a plasmid made byThermo Open Biosystems Human ORFeome version 5.1 #1362
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Plasmid for stable expression of human ID2 with C-terminal V5 tag.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pLX302 ID2-V5 puro was a gift from Kevin Janes (Addgene plasmid # 83096 ; http://n2t.net/addgene:83096 ; RRID:Addgene_83096) -
For your References section:
Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer. Bajikar SS, Wang CC, Borten MA, Pereira EJ, Atkins KA, Janes KA. Dev Cell. 2017 Nov 20;43(4):418-435.e13. doi: 10.1016/j.devcel.2017.10.027. 10.1016/j.devcel.2017.10.027 PubMed 29161592